ACADIA Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

CEO

Catherine Owen Adams

CEOCatherine Owen Adams

Employees

654

Employees654

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1993

Founded1993

Employees

654

Employees654

ACAD Key Statistics

Market cap

4.16B

Market cap4.16B

Price-Earnings ratio

17.74

Price-Earnings ratio17.74

Dividend yield

—

Dividend yield—

Average volume

1.93M

Average volume1.93M

High today

$24.87

High today$24.87

Low today

$23.49

Low today$23.49

Open price

$23.63

Open price$23.63

Volume

2.78M

Volume2.78M

52 Week high

$26.65

52 Week high$26.65

52 Week low

$13.40

52 Week low$13.40

ACAD News

TipRanks 4d

Acadia Pharmaceuticals publishes interim LOTUS study data in journal

Acadia Pharmaceuticals (ACAD) announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observ...

TipRanks 5d

Acadia Pharmaceuticals price target raised to $39 from $35 at TD Cowen

TD Cowen raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $39 from $35 and keeps a Buy rating on the shares. The firm noted the company is exp...

Analyst ratings

65%

of 20 ratings

Buy

65%

Hold

30%

Sell

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.